NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CARDURA XL (doxazosin mesylate) by Viatris is (bph), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). First approved in 2005.
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDURA XL is an extended-release oral tablet containing doxazosin mesylate, a selective alpha-1 adrenergic receptor antagonist indicated for benign prostatic hyperplasia (BPH). It relieves BPH symptoms by blocking alpha-1 receptors in the prostate and bladder neck, reducing urethral resistance and improving urine flow. The drug addresses both the dynamic (smooth muscle tone) and static (obstruction) components of lower urinary tract symptoms.
$0.804MPart D
LOE ApproachingDeclining
As LOE approaches, the commercial team will contract and shift focus to generic lifecycle management and niche positioning rather than growth initiatives.
Mechanism of Action
(BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
Started May 2009
989 enrolled
Prostatic Hyperplasia
Worked on CARDURA XL at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.